Please sign in to follow a disease.

Hikma Pharmaceuticals LLC

Clinical trials sponsored by Hikma Pharmaceuticals LLC, explained in plain language.

Now part of Hikma Pharmaceuticals PLC HIK LONDON

Generic and specialty pharmaceutical manufacturer.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Not yet finished but already full! 1 Completed 1

Compassionate use study offers AML patients continued access to experimental oral chemo

Disease control Ongoing

This study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine after they finished a previous trial. The main goal is to track any side effects and see how safe the drug is over a longer period. Abo…

Sponsor: Hikma Pharmaceuticals LLC • Aim: Disease control

Last updated Jun 27, 2026 08:11 UTC

Hikma Pharmaceuticals LLC

Compassionate use study offers AML patients continued access to experimental oral chemo